Achillion to host conference call Conference call to provide an update on the company's hepatitis C (HCV) development programs and 4Q12 earnings results will be held on February 20 at 5 pm. Webcast Link
News For ACHN From The Last 14 Days
Check below for free stories on ACHN the last two weeks.
Achillion sees FY14 EPS to approach (70c), consensus (81c) The company expects that research and development expenses during 2014 will be approximately $55M-60M and that net cash used in operating activities in 2014 will be approximately $60M-65M based on current operating plans, anticipated timelines and the estimated cost of clinical trials and product development programs.